Adverum Biotechnologies
Adverum Biotechnologies Inc. ( NASDAQ: ADVM)
Jason Awe
Executive Director of Corporate Communications and Investor Relations
Corporate Speaker
Jason Awe, PhD, MBA, is Executive Director of Corporate Communications and Investor Relations at Adverum Biotechnologies. He brings over a decade of experience in biopharma communications, investor relations, and scientific affairs. At Adverum, he leads strategic corporate messaging, media relations, and investor engagement. Previously, he led Corporate Communications and IR at Atara Biotherapeutics, where he oversaw communications during the approval of the world’s first allogeneic T-cell therapy. In that role, he also served as the primary liaison between the company and the external investment community, communicating strategy, results, and expectations across a variety of public forums. Earlier at Amgen, Dr. Awe held leadership roles across global value strategy, policy communications, and medical affairs—shaping narratives on drug pricing and biosimilars, supporting product launches, and driving external engagement. He holds a PhD from UCLA’s David Geffen School of Medicine,
an MBA from UCLA Anderson, and a BS from UC Santa Barbara.
Adverum Biotechnologies Inc. ( NASDAQ: ADVM)
Company Profile
Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, Ixo-vec, as a one-time, intravitreal injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
